Insmed website is up (8:15 ET). Looks updated, but it has been awhile since I accessed it, and it does not mention Iplex.
"At Insmed we are on a mission to transform the lives of patients battling serious rare diseases. We are developing novel, targeted therapies to help serve the critical unmet needs of these patients. In concert with developing therapeutic solutions, we are committed to improving the entire patient experience, from diagnosis and treatment to everyday living."
"Insmed’s commitment and responsibility to patients has no borders. We have offices in six countries, INS-212 CONVERT™ clinical trial sites in over 15, and our employees all over the world are dedicated to making a global impact."
That is about 50% of SP you were originally targeting, has something changed? Just asking, as I have been away from the mb for a bit.
Merry Christmas and a joy-filled new year!
Not sure if there is any significance to this.
"Abandonment Notice! On Monday, December 14, 2015, status on the LONSPIRA trademark changed to ABANDONED - NO STATEMENT OF USE FILED.
Abandonment Notice! On Monday, December 14, 2015, status on the LONSPIRA trademark changed to ABANDONED - NO STATEMENT OF USE FILED.
Abandonment Notice! On Monday, December 14, 2015, status on the VONCERA trademark changed to ABANDONED - NO STATEMENT OF USE FILED.
Status Update! On Monday, December 14, 2015, status on the VONCERA trademark changed to ABANDONED - NO STATEMENT OF USE FILED."
Well done on your TGTX investment! The slide in SP since July has been disappointing, I have been in and out in last 12 months or so. What are your thoughts about this ticker for 2016?
TGTX had a RS on July 14, 2011. This was a 1 for 50 reverse split and way before my time of when I became involved with this stock. GL here Frank.
Combination of TG-1101 plus TGR-1202 ("TG-1303") continues to demonstrate a favorable safety profile, with only 8% of patients discontinuing due to an adverse event and no cases of colitis reported to date
80% (8 of 10) ORR in patients with relapsed refractory CLL/SLL treated in the higher dose cohort of TG-1303, including 1 CR and 7 PR's and the remaining 2 patients with stable disease, one still on study with significant reduction in tumor burden (CLL evaluated per iwCLL 2008 criteria)
71% (12 of 17) ORR, including 24% CRs, in patients with heavily pretreated relapsed/refractory Follicular Lymphoma (FL) & Marginal Zone Lymphoma (MZL) treated in the higher dose cohort of TG-1303
35% (6 of 17) ORR in patients with relapsed/refractory DLBCL and Richter's transformation (large cell lymphoma) treated in the higher dose cohort of TG-1303
TGR-1202 based combination therapy with the glycoengineered anti-CD20 mAb, obinutuzumab, plus chlorambucil achieved 100% (15 of 15) ORR in treatment naïve CLL patients, with 33% of patients achieving a CR, and 47% of patients achieving MRD negativity.
Read full release of announcement on TGTX website. GLTAL.